Chronic Kidney Disease in Pakistani Population (CKD)
Recruitment status was: Recruiting
The Indo-Asian developing countries are facing an epidemic of chronic diseases including hypertension, diabetes and chronic kidney disease (CKD). Diagnosis of early CKD is essential for institution of effective and timely prevention of its complications; costly late stage treatment for end stage renal disease is currently an unfeasible option in these populations. GFR estimates of kidney function provide a common reference standard for all people and are therefore readily applicable by physicians and understood by patients. However, the existing GFR equations yield widely discrepant results in the Indo Asian population, and none of the currently available estimating equations have been validated in this population.
The main objective is to develop a tool which can be used for screening subjects at high risk for developing CKD (with hypertension and diabetes) as well as the general population.
|Chronic Kidney Disease|
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Chronic Kidney Disease in the Pakistani Population|
- GFR will be measured as the mean of at least two urinary clearance periods of Inulin
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||April 2010|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
The proposed study is being conducted at the Aga Khan University in collaboration with Tufts-New England Medical Center and Imperial College, UK. It is a population based cross-sectional study using a 2-stage cluster design. The study would be performed on 650 adult subjects from the general population in Karachi.
A new GFR equation specific to a Pakistani population would be developed and validated using the gold standard of measured Insulin GFR. The performance of the new equation will be compared to the existing ones developed in other populations with respect to bias, precision, and accuracy.
The project is likely to contribute significantly to moving the field to kidney disease forward, and its results are likely to have far reaching implications for understanding of CKD and, ultimately, its prevention in Indo-Pakistani populations worldwide.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00800878
|Contact: Tazeen H Jafar, MD, MPH||92 21 4930051 ext firstname.lastname@example.org|
|Aga Khan University||Recruiting|
|Karachi, Sindh, Pakistan, 74800|
|Principal Investigator:||Tazeen H Jafar, MD, MPH||Aga Khan University|